A Phase 2 interventional study of Cabozantinib and Best Supportive Care (BSC) in Osteosarcoma, Osteosarcoma in Children and Osteosarcoma in Adolescents and Young Adults, sponsored by Ipsen. Terminated at 16 sites in 10 countries. Open to participants aged 5 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Ipsen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing cabozantinib in Osteosarcoma — 5 open to participants now, 7 under way, 1 of them phase 3. cabozantinib · Osteosarcoma.
Among the 10 studies testing cabozantinib in Osteosarcoma, this one is the 10th largest by enrollment, is the only one that started in 2024, is one of 6 in phase 2, and was the 9th registered.
488 studies on the registry are indexed under Osteosarcoma; 123 are open to participants now.
Browse Osteosarcoma studies →5 of the 10 studies testing cabozantinib in Osteosarcoma are open now, in 9 countries. Recruiting first, the newest first:
Gustave Roussy, Cancer Campus, Grand Paris · Sites in Denmark, Finland, France and 5 more countries
Ages 4+
Children's Hospital of Philadelphia · Sites in United States
Ages 5–40
M.D. Anderson Cancer Center · Sites in United States
Ages 12+
Nationwide Children's Hospital · Sites in United States
Ages 18 mo–40 yrs
Institut Bergonié · Sites in France
Ages 18+
By country, each count listing its studies:
cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 100 Osteosarcoma studies recruiting now, 41 (41%) set no upper age limit and 55 (55%) stop at 75 or younger; 75 take children under 18; 3 take healthy volunteers.
This study: 5 Years to 30 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cabozantinib is the treatment under test here. Read study by study →
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 2
First in 2014; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 40 across 354 interventional studies indexed under Osteosarcoma.
Median enrollment 88 across the 10 interventional studies. Of the 2 that completed or were terminated, 1 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 10 have an industry lead sponsor. The 8 most frequent:
Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
Ipsen has 1 study filed under Osteosarcoma — fewer than ten, so there is no comparison to draw.
2 of the studies testing cabozantinib in Osteosarcoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05182164Institut BergoniéCombination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas | 2026-12 |
| NCT06156410Children's Hospital of PhiladelphiaCabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing cabozantinib in Osteosarcoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The participants of this study will be children, adolescents, and young adults with residual osteosarcoma, which cannot be removed completely through surgery.
Participants will have achieved a partial response or stable disease at the end of conventional chemotherapy. Osteosarcoma is cancer of the bone. The cancer cells make immature bone cells, known as osteoid.
Osteosarcoma is very rare, but it is the most common type of bone cancer in children and teens. It is most common in teens and young adults.
In this study, participants will receive either cabozantinib and best supportive care or the best supportive care alone. Best supportive care will be provided at the investigator's discretion and according to institutional guidelines.
It includes antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including radiotherapy), etc. but does not include tumor specific therapy.
Cabozantinib will be taken by mouth (orally), as a tablet, once a day. Cabozantinib will be provided to participants who tolerate it for as long as their disease does not progress. Participants in the study receiving best supportive care alone may switch to treatment with cabozantinib and best supportive care if their disease progresses and if other eligibility criteria are met.
Participants may withdraw consent to participate at any time.
The estimated duration of the study for participants is 24 months, however a participant could remain in the study longer if demonstrating treatment benefit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive cabozantinib and BSC.
Drug: Cabozantinib · Other: Best Supportive Care (BSC)
Participants will receive BSC alone administered per investigator's discretion and institutional guidelines.
Other: Best Supportive Care (BSC)
Participants will receive cabozantinib orally Once daily (QD) on a continuous dosing schedule for cycles of 28 days.
Participants will receive BSC. BSC includes antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. but does not include tumor specific therapy.
Participants will receive BSC alone. BSC includes antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. but does not include tumor specific therapy.
Progression-free Survival (PFS) Assessed by Blinded Independent Radiology Committee (BIRC)
PFS was defined as the time from the date of randomization (Cycle 1 Day 1) to the data of first documented disease progression (according to Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1) or the date of death due to any cause, whichever occurred first.
Time frame: Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months
Progression-free Survival Rate at 4 Months and 1 Year Assessed by Blinded Independent Radiology Committee
PFS rate at 4 months and 1 year was defined as the percentage of participants who were not progressed by BIRC assessment using RECIST version 1.1 at 4 months and 1 year.
Time frame: At 4 months and 1 year after randomization (Cycle 1 Day 1)
Objective Response Rate (ORR) Assessed by Blinded Independent Radiology Committee
ORR was defined as the percentage of participants who had achieved complete response (CR) or partial response (PR) determined by BIRC using RECIST version 1.1. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) with reduction in short axis to \<10 millimeter (mm). PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months
Disease Control Rate (DCR) Assessed by Blinded Independent Radiology Committee
DCR was defined as the percentage of participants who had achieved CR, PR, or stable disease (SD) determined by BIRC using RECIST version 1.1. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) with reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for progressive disease (PD). PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study), in addition to the relative increase of 20%, the sum must have also demonstrated an absolute increase of at least 5 mm.
Time frame: Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months
Progression-free Survival Assessed by Investigator
PFS was defined as the time from the date of randomization (Cycle 1 Day 1) to the data of first documented disease progression (according to RECIST version 1.1) or the date of death due to any cause, whichever occurred first.
Time frame: Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months
Progression-free Survival Rate at 4 Months and 1 Year Assessed by Investigator
PFS rate at 4 months and 1 year was defined as the percentage of participants who were not progressed by investigator assessment using RECIST version 1.1 at 4 months and 1 year.
Time frame: At 4 months and 1 year after randomization (Cycle 1 Day 1)
Objective Response Rate Assessed by Investigator
ORR was defined as the percentage of participants who had achieved CR or PR determined by investigator using RECIST version 1.1. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) with reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months
Disease Control Rate Assessed by Investigator
DCR was defined as the percentage of participants who had achieved CR, PR, or SD determined by investigator using RECIST version 1.1. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) with reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PD. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study), in addition to the relative increase of 20%, the sum must have also demonstrated an absolute increase of at least 5 mm.
Time frame: Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months
Overall Survival (OS)
The OS was defined as the time from date of randomization to the date of death, from any cause.
Time frame: Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months
Overall Survival Rate at 1 Year
The OS rate was defined as the percentage of participants alive at 1 year.
Time frame: At 1 year after randomization (Cycle 1 Day 1)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events (TESAEs) and Events to Monitor (ETM)
Adverse events (AEs) were defined as any untoward medical occurrence in a clinical study participant to whom a medicinal product was administered, and which did not necessarily have a causal relationship with the treatment. SAE was defined as any medical occurrence that, at any dose, meets one or more of the criteria listed: resulted in death, was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; other medically important situations; was a suspected transmission of any infectious agent via an authorized medicinal product. ETM were AEs that may not be serious but were of special importance to a particular drug or class of drugs. TEAEs defined as any AE that started or worsened on or after the first dose of study treatment up to the earliest of death, loss to follow-up, consent withdrawal, last dose of study treatment + 30 days, or data cut-off.
Time frame: From the first study treatment administration (Cycle 1 Day 1) up to early termination of the study, approximately 12 months
Area Under the Plasma Concentration Time Curve (AUC) at Steady State of Cabozantinib
Blood samples were planned to be collected at specified timepoints for analysis of AUC.
Time frame: Pre-dose and 4 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1
Average Concentration (Cavg) at Steady State of Cabozantinib
Blood samples were planned to be collected at specified timepoints for analysis of Cavg.
Time frame: Pre-dose and 4 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1
Minimum Observed Plasma Drug Concentration (Cmin) at Steady State of Cabozantinib
Blood samples were planned to be collected at specified timepoints for analysis of Cmin.
Time frame: Pre-dose and 4 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1
Maximal Observed Plasma Drug Concentration (Cmax) at Steady State of Cabozantinib
Blood samples were planned to be collected at specified timepoints for analysis of Cmax.
Time frame: Pre-dose and 4 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1
Acceptability and Palatability of Cabozantinib Tablets Using a Horizontal Visual Assessment Scale
Acceptability and palatability of cabozantinib tablets in participants were planned to be assessed using a 5-point facial hedonic scale (FHS) with a correlated horizontal 100-point visual assessment scale (VAS). The face scale to assess palatability had 5 response options- very bad, bad, neither good or bad, good, very good. The VAS score ranged from 0 (least palatable) to 100 (most palatable), with higher scores indicating better palatability and acceptability.
Time frame: Cycle 1 Day 1
Change From Baseline in Score for All Paediatric Quality of Life (QoL) Inventory (PedsQL) Scales Including Generic Core Scales and Cancer Modules Throughout the Study
The PedsQL a modular instrument was planned to measure health-related quality of life (HRQoL) in participants \<18 years of age. The PedsQL Generic Core Scales are multidimensional child self-report and parent proxy-report scales developed as the generic core measure to be integrated with the PedsQL disease specific modules. It assesses pain and hurt; nausea, procedural and treatment anxiety; worry, cognitive problems; perceived physical appearance, and communication. The scores for each subcategories are ranged from 0 (never) to 4 (almost always) .The total scores range from 0 to 100, with higher scores indicating better health related quality of life. Baseline was defined as the last non-missing measurement on or prior to the date of randomization.
Time frame: From the first dose of study treatment (Cycle 1 Day 1) up to early termination of the study, approximately 12 months
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Throughout the Study
EORTC QLQ-C30 was planned to assess HRQoL, functioning, and symptoms in adult participants. It is a 30-item self-administered questionnaire for all cancer types. Questions are grouped into 5 multi-item functional scales (physical, role, emotional, cognitive, and social), 3 multi-item symptom scales (fatigue, pain, and nausea/vomiting), a 2-item global QoL scale, 5 single items assessing additional symptoms commonly reported by cancer patients (dyspnea, loss of appetite, insomnia, constipation, and diarrhea), and 1 item on financial impact of disease. All but 2 questions have 4-point scales ranged from 0 (not at all) and 4 (very much) and 2 questions concerning global health status and QoL have 7-point scales ranged from 0 (very poor) to 7 (excellent). Total scores ranged from 0 to 100, where higher scores indicated better functioning, better HRQoL, or greater level of symptoms. Baseline was defined as last non-missing measurement on or prior to the date of randomization.
Time frame: From the first dose of study treatment (Cycle 1 Day 1) up to early termination of the study, approximately 12 months
This Phase II, open-label, multicenter, randomized study was conducted in participants with unresectable residual osteosarcoma in 5 countries between 22 November 2024 and 27 February 2026. The sponsor decided to stop study enrollment due to persistent recruitment challenges and the study was terminated.
| Milestone | Cabozantinib + BSC | BSC Alone |
|---|---|---|
| Started | 5 | 5 |
| Treated | 5 | 3 |
| Safety set | 5 | 3 |
| Completed | 3 | 2 |
| Not completed | 2 | 3 |
| Withdrew: Progressive disease | 1 | 1 |
| Withdrew: Other | 1 | 0 |
| Withdrew: Randomized but not treated | 0 | 2 |
PFS was defined as the time from the date of randomization (Cycle 1 Day 1) to the data of first documented disease progression (according to Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1) or the date of death due to any cause, whichever occurred first.
No measurements were reported for this outcome.
PFS rate at 4 months and 1 year was defined as the percentage of participants who were not progressed by BIRC assessment using RECIST version 1.1 at 4 months and 1 year.
No measurements were reported for this outcome.
ORR was defined as the percentage of participants who had achieved complete response (CR) or partial response (PR) determined by BIRC using RECIST version 1.1. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) with reduction in short axis to \<10 millimeter (mm). PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
No measurements were reported for this outcome.
DCR was defined as the percentage of participants who had achieved CR, PR, or stable disease (SD) determined by BIRC using RECIST version 1.1. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) with reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for progressive disease (PD). PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study), in addition to the relative increase of 20%, the sum must have also demonstrated an absolute increase of at least 5 mm.
No measurements were reported for this outcome.
PFS was defined as the time from the date of randomization (Cycle 1 Day 1) to the data of first documented disease progression (according to RECIST version 1.1) or the date of death due to any cause, whichever occurred first.
No measurements were reported for this outcome.
PFS rate at 4 months and 1 year was defined as the percentage of participants who were not progressed by investigator assessment using RECIST version 1.1 at 4 months and 1 year.
No measurements were reported for this outcome.
ORR was defined as the percentage of participants who had achieved CR or PR determined by investigator using RECIST version 1.1. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) with reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
No measurements were reported for this outcome.
DCR was defined as the percentage of participants who had achieved CR, PR, or SD determined by investigator using RECIST version 1.1. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) with reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PD. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study), in addition to the relative increase of 20%, the sum must have also demonstrated an absolute increase of at least 5 mm.
No measurements were reported for this outcome.
The OS was defined as the time from date of randomization to the date of death, from any cause.
No measurements were reported for this outcome.
The OS rate was defined as the percentage of participants alive at 1 year.
No measurements were reported for this outcome.
Adverse events (AEs) were defined as any untoward medical occurrence in a clinical study participant to whom a medicinal product was administered, and which did not necessarily have a causal relationship with the treatment. SAE was defined as any medical occurrence that, at any dose, meets one or more of the criteria listed: resulted in death, was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; other medically important situations; was a suspected transmission of any infectious agent via an authorized medicinal product. ETM were AEs that may not be serious but were of special importance to a particular drug or class of drugs. TEAEs defined as any AE that started or worsened on or after the first dose of study treatment up to the earliest of death, loss to follow-up, consent withdrawal, last dose of study treatment + 30 days, or data cut-off.
| Participants | Cabozantinib + BSC | BSC Alone |
|---|---|---|
| TEAEs | 5 | 3 |
| TESAEs | 2 | 0 |
| ETM | 5 | 3 |
Blood samples were planned to be collected at specified timepoints for analysis of AUC.
No measurements were reported for this outcome.
Blood samples were planned to be collected at specified timepoints for analysis of Cavg.
No measurements were reported for this outcome.
Blood samples were planned to be collected at specified timepoints for analysis of Cmin.
No measurements were reported for this outcome.
Blood samples were planned to be collected at specified timepoints for analysis of Cmax.
No measurements were reported for this outcome.
Acceptability and palatability of cabozantinib tablets in participants were planned to be assessed using a 5-point facial hedonic scale (FHS) with a correlated horizontal 100-point visual assessment scale (VAS). The face scale to assess palatability had 5 response options- very bad, bad, neither good or bad, good, very good. The VAS score ranged from 0 (least palatable) to 100 (most palatable), with higher scores indicating better palatability and acceptability.
No measurements were reported for this outcome.
The PedsQL a modular instrument was planned to measure health-related quality of life (HRQoL) in participants \<18 years of age. The PedsQL Generic Core Scales are multidimensional child self-report and parent proxy-report scales developed as the generic core measure to be integrated with the PedsQL disease specific modules. It assesses pain and hurt; nausea, procedural and treatment anxiety; worry, cognitive problems; perceived physical appearance, and communication. The scores for each subcategories are ranged from 0 (never) to 4 (almost always) .The total scores range from 0 to 100, with higher scores indicating better health related quality of life. Baseline was defined as the last non-missing measurement on or prior to the date of randomization.
No measurements were reported for this outcome.
EORTC QLQ-C30 was planned to assess HRQoL, functioning, and symptoms in adult participants. It is a 30-item self-administered questionnaire for all cancer types. Questions are grouped into 5 multi-item functional scales (physical, role, emotional, cognitive, and social), 3 multi-item symptom scales (fatigue, pain, and nausea/vomiting), a 2-item global QoL scale, 5 single items assessing additional symptoms commonly reported by cancer patients (dyspnea, loss of appetite, insomnia, constipation, and diarrhea), and 1 item on financial impact of disease. All but 2 questions have 4-point scales ranged from 0 (not at all) and 4 (very much) and 2 questions concerning global health status and QoL have 7-point scales ranged from 0 (very poor) to 7 (excellent). Total scores ranged from 0 to 100, where higher scores indicated better functioning, better HRQoL, or greater level of symptoms. Baseline was defined as last non-missing measurement on or prior to the date of randomization.
No measurements were reported for this outcome.
Collected over SAEs, other AEs and all-cause mortality data was collected from the first dose of study treatment (Cycle 1 Day 1) up to early termination of the study, approximately 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cabozantinib + BSC | 1/5 (20%) | 2/5 (40%) | 5/5 (100%) |
| BSC Alone | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Event | Cabozantinib + BSC | BSC Alone |
|---|---|---|
| Influenza like illnessGeneral disorders | 1/5 | 0/3 |
| ParaesthesiaNervous system disorders | 1/5 | 0/3 |
| Event | Cabozantinib + BSC | BSC Alone |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/5 | 3/3 |
| DiarrhoeaGastrointestinal disorders | 4/5 | 1/3 |
| Aspartate aminotransferase increasedInvestigations | 4/5 | 0/3 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/5 | 2/3 |
| LeukopeniaBlood and lymphatic system disorders | 1/5 | 2/3 |
| NauseaGastrointestinal disorders | 3/5 | 0/3 |
| StomatitisGastrointestinal disorders | 3/5 | 0/3 |
| Blood bilirubin increasedInvestigations | 3/5 | 0/3 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 3/5 | 0/3 |
| FatigueGeneral disorders | 2/5 | 0/3 |
The intent-to-treat set included all participants who were randomized to study treatment.
| Age, Continuous(years) | Cabozantinib + BSC | BSC Alone | Total |
|---|---|---|---|
| Mean | 21.6 ± 6.74 | 18.2 ± 7.02 | 19.9 ± 6.74 |
| Sex: Female, Male(Participants) | Cabozantinib + BSC | BSC Alone | Total |
|---|---|---|---|
| Female | 2 | 2 | 4 |
| Male | 3 | 3 | 6 |
| Race/Ethnicity, Customized(Participants) | Cabozantinib + BSC | BSC Alone | Total |
|---|---|---|---|
| American Indian or Alaskan Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Black or African American | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| White | 4 | 4 | 8 |
| Not Reported | 1 | 0 | 1 |
| Unknown | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Data sharing details ↗ · www.ipsen.com
Ran from Nov 2024 to primary completion in Feb 2026, 15 months.
Results were first posted in Oct 2026, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabozantinib